PDB69 DETERMINANTS OF STOPPING TREATMENT WITH ORAL ANTIDIABETIC DRUGS IN DAILY CLINICAL PRACTICE

This study aimed to estimate the efficacy and safety of intermediate-acting insulin Rosinsulin C in patients with type 2 diabetes mellitus inadequately controlled with oral antidiabetic drugs.The present study is a 6-month, prospective, uncontrolled, clinical experience evaluation study using insulin Rosinsulin С for type 2 diabetes patients in daily clinical practice. Episodes of hypoglycaemia, adverse events were recorded. The study included 28 patients with type 2 diabetes, 4 men and 24 women who treated with metformin in combination with sulfonylureas in the highest dose. Indicators of glycosylated hemoglobin (HbA1c) of 8 to 14%, the median HbA1c was 11 (10; 13)% of patients age 65 (57; 72) years, body mass index – 33 (30; 35) kg/m2, waist circumference – 105 (99; 111) cm, diabetes duration – 7 (2; 11) years. With the introduction of Rosinsulin С cartridges carried pen Autopen. At the start of the study and after 3 and 6 months, determined the level of HbA1c, fasting plasma glucose.After 6 months' treatment with Rosinsulin С in combination with oral antidiabetic drugs HbA1c was significantly lowered (–3%) (p = 0,001), fasting plasma glucose level decreased by 5 mmol/L (p = 0,001). There was not severe hypoglycemia during the observation period.This research showed that Rosinsulin C is effective and safe in the treatment of patients with type 2 diabetes who were decompensated with oral antidiabetic drugs and can be recommended for use as the initiation of insulin therapy in routine clinical practice.

Download Full-text

Abstract #292 Efficacy of Hydroxychloroquine when added in Subjects with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Basal Insulin and Two Other Oral Antidiabetic Drugs

Endocrine Practice ◽

10.1016/s1530-891x(20)46636-4 ◽

2019 ◽

Vol 25 ◽

pp. 119-120

Author(s):

Arjun Baidya ◽

Ajay Chhabra

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Basal Insulin ◽

Antidiabetic Drugs ◽

Oral Antidiabetic Drugs ◽

Oral Antidiabetic

Download Full-text

2224-PUB: Comparative Effectiveness of Second-Line Initiation of Basal Insulin Therapy vs. Oral Antidiabetic Drugs Added to Metformin among Patients with Type 2 Diabetes in Taiwan

Diabetes ◽

10.2337/db19-2224-pub ◽

2019 ◽

Vol 68 (Supplement 1) ◽

pp. 2224-PUB

Author(s):

PIN-HAO CHEN ◽

SHIHCHEN KUO ◽

HUANG-TZ OU

Keyword(s):

Type 2 Diabetes ◽

Insulin Therapy ◽

Comparative Effectiveness ◽

Basal Insulin ◽

Antidiabetic Drugs ◽

Second Line ◽

Oral Antidiabetic Drugs ◽

Oral Antidiabetic

Download Full-text

Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study

Pituitary ◽

10.1007/s11102-021-01161-4 ◽

2021 ◽

Author(s):

Susan L. Samson ◽

Feng Gu ◽

Ulla Feldt-Rasmussen ◽

Shaoling Zhang ◽

Yerong Yu ◽

...

Keyword(s):

Cushing’S Disease ◽

Rescue Therapy ◽

Antidiabetic Drugs ◽

Cushing's Disease ◽

Oral Antidiabetic Drugs ◽

Open Label ◽

Oral Antidiabetic ◽

Open Label Phase ◽

Core Phase ◽

Phase Iv

Abstract Purpose Pasireotide is an effective treatment for acromegaly and Cushing’s disease, although treatment-emergent hyperglycemia can occur. The objective of this study was to assess incretin-based therapy versus insulin for managing pasireotide-associated hyperglycemia uncontrolled by metformin/other permitted oral antidiabetic drugs. Methods Multicenter, randomized, open-label, Phase IV study comprising a core phase (≤ 16-week pre-randomization period followed by 16-week randomized treatment period) and optional extension (ClinicalTrials.gov ID: NCT02060383). Adults with acromegaly (n = 190) or Cushing’s disease (n = 59) received long-acting (starting 40 mg IM/28 days) or subcutaneous pasireotide (starting 600 µg bid), respectively. Patients with increased fasting plasma glucose (≥ 126 mg/dL on three consecutive days) during the 16-week pre-randomization period despite metformin/other oral antidiabetic drugs were randomized 1:1 to open-label incretin-based therapy (sitagliptin followed by liraglutide) or insulin for another 16 weeks. The primary objective was to evaluate the difference in mean change in HbA1c from randomization to end of core phase between incretin-based therapy and insulin treatment arms. Results Eighty-one (32.5%) patients were randomized to incretin-based therapy (n = 38 received sitagliptin, n = 28 subsequently switched to liraglutide; n = 12 received insulin as rescue therapy) or insulin (n = 43). Adjusted mean change in HbA1c between treatment arms was – 0.28% (95% CI – 0.63, 0.08) in favor of incretin-based therapy. The most common AE other than hyperglycemia was diarrhea (incretin-based therapy, 28.9%; insulin, 30.2%). Forty-six (18.5%) patients were managed on metformin (n = 43)/other OAD (n = 3), 103 (41.4%) patients did not require any oral antidiabetic drugs and 19 patients (7.6%) were receiving insulin at baseline and were not randomized. Conclusion Many patients receiving pasireotide do not develop hyperglycemia requiring oral antidiabetic drugs. Metformin is an effective initial treatment, followed by incretin-based therapy if needed. ClinicalTrials.gov ID: NCT02060383.

Download Full-text